Stephen D. Ferrone, President and CEO of Immunosyn, stated, "Utah Biopharmaceutical Laboratories sought the ability to distribute SF-1019 in the State of Utah as a result of the compelling desire of patients who are seeking this treatment after their having failed conventional, FDA approved therapy. This patient demand stemmed from the perceived benefit of treatment in patients who participated in early preclinical studies and who desire ongoing access to SF-1019 to alleviate their symptoms."
Ferrone added, "Argyll Biotech advises us that they plan to continue the process to obtain full regulatory approvals for the marketing of SF-1019 in both Europe and the U.S."
"This is an exciting early-stage development as this puts revenue producing capabilities within short-term range for the company," stated Douglas A. McClain, Jr., Chairman of the Board and CFO of Immunosyn.
About Utah Biopharmaceutical Laboratories, LLC
Utah Biopharmaceutical Laboratories was organized for the purpose of manufacturing SF-1019 for administering and distributing by United Biopharmaceutical Laboratories through the Renewed Hope Clinic under the direction of Mitchell J. Melling, MD in the State of Utah.
About Renewed Hope Clinic
Located in Beaver, Utah at 95 North 400 East, Renewed Hope Clinic is managed by Mitchell Melling, MD who is Board Certified in Family Practice in the State of Utah. Renewed Hope Clinic is a family practice center, emphasizing treatment of autoimmune and infectious diseases.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board:
IMYN) plans to market and distribute life enhancing therapeutics.
Currently, the company has exclusive worldwide rights from its largest
shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute
SF-1019, a compound that was developed from extensive research into
Biological Response Modifi
|SOURCE Immunosyn Corporation|
Copyright©2008 PR Newswire.
All rights reserved